See the DrugPatentWatch profile for onivyde
Onivyde (nal-IRI) is a liposomal encapsulation of irinotecan, a topoisomerase I inhibitor [1]. It is used in combination with leucovorin and fluorouracil for the treatment of patients with metastatic adenocarcinoma of the pancreas [1].
What is the mechanism of action for Onivyde?
Onivyde works by targeting cancer cells that have metastasized in the pancreas [1]. As a liposomal encapsulation of irinotecan, it acts as a topoisomerase I inhibitor, which interferes with DNA replication and repair processes in cancer cells, leading to cell death [1].
How is Onivyde administered and what are the typical dosages?
Onivyde is administered intravenously [1]. The recommended dose is 80 mg/m2 every two weeks [1]. This is given in combination with leucovorin and fluorouracil [1].
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, abdominal pain, and stomatitis [1]. Serious adverse reactions may include severe diarrhea, neutropenia, and febrile neutropenia [1].
What is the current patent and exclusivity status for Onivyde?
Information regarding the specific patent and exclusivity status for Onivyde, including potential patent expiry dates, can be found on DrugPatentWatch.com [2]. This resource tracks patent information and regulatory exclusivities for pharmaceutical products.
Are there any clinical trials or studies evaluating Onivyde?
Onivyde has been evaluated in clinical trials, including the metastatic pancreatic cancer setting [1]. Ongoing research may explore its efficacy in different patient populations or in combination with other therapies.
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals, Inc [1].
What are the treatment guidelines for metastatic pancreatic cancer that include Onivyde?
Onivyde is indicated for patients with metastatic adenocarcinoma of the pancreas who have been previously treated with a fluoropyrimidine-based chemotherapy [1]. It is given as part of a combination regimen.
Where can I find more detailed drug information and safety data for Onivyde?
More comprehensive information about Onivyde, including detailed prescribing information, clinical pharmacology, and safety data, is available through official drug information resources and the manufacturer's website [1].
How does Onivyde compare to other treatments for metastatic pancreatic cancer?
Onivyde is indicated for patients who have progressed on a fluoropyrimidine-based chemotherapy [1]. Its role is in the second-line treatment setting, often following initial chemotherapy.
What are the risks associated with Onivyde treatment?
Key risks include severe gastrointestinal toxicity such as diarrhea, which can be life-threatening [1]. Hematologic toxicities, including neutropenia and febrile neutropenia, are also significant risks that require monitoring [1].
What is the prognosis for patients treated with Onivyde?
Onivyde is part of a treatment regimen aimed at managing metastatic pancreatic cancer, a condition with a generally poor prognosis. Clinical trials have demonstrated improvements in progression-free survival and overall survival for patients treated with Onivyde in combination therapy [1].
Can Onivyde be used in patients with other types of cancer?
Currently, Onivyde is specifically indicated for metastatic adenocarcinoma of the pancreas [1]. Its use in other cancer types may be explored in clinical trials.
What is the typical duration of Onivyde treatment?
Treatment with Onivyde is typically continued as long as the patient is benefiting from the therapy and tolerating the side effects [1]. The exact duration depends on individual patient response and physician assessment.
What are the challenges in treating metastatic pancreatic cancer with Onivyde?
Challenges include managing the significant gastrointestinal and hematologic toxicities associated with the drug, as well as the inherent aggressiveness of metastatic pancreatic cancer [1].
---
Sources:
[1] National Institutes of Health. (n.d.). Onivyde. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10e626d9-16b1-46b9-a602-551a74c69056
[2] DrugPatentWatch.com. (n.d.). https://drugpatentwatch.com/